Medivir reports 24-week interim Juncture 2b results of TMC435 in treatment-naïve patients with HCV genotype-1
Formidable and steadfast antiviral efficacy was demonstrated at 24-week end-of-treatment and in interim SVR4 and SVR12 results. There were no clinically apt differences between TMC435 treatment groups and placebo as far as something adverse events.
“We also are looking ahead to the top-line figures coming up from the facet 2b checking C206 (ASPIRE) in treatment-experienced patients later this year as justly as start of viewpoint 3 clinical trials in treatment-naïve patients betimes next year.”
Medivir (STO:MVIRB) announced today 24-week end-of-treatment interim results from the 5-arm slant gradually introduce 2b reply guided PROP contemplate in 386 treatment-naïve patients with hepatitis C virus (HCV) genotype-1 (TMC435-C205).
TMC435 is a protease inhibitor jointly developed before Medivir and Tibotec Pharmaceuticals, dosed as identical capsule in a minute everyday (q.d.) to discuss hepatitis C virus infections (HCV).
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
